UK markets open in 31 minutes
NIKKEI 225
37,628.48 -831.60 (-2.16%) HANG SENG
17,214.16 +12.89 (+0.07%) CRUDE OIL
82.97 +0.16 (+0.19%) GOLD FUTURES
2,330.10 -8.30 (-0.35%) DOW
38,460.92 -42.77 (-0.11%) Bitcoin GBP
51,481.50 -1,871.79 (-3.51%)
TScan Therapeutics, Inc. (TCRX)
NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
| Previous close | 7.26 |
| Open | 7.28 |
| Bid | 7.32 x 400 |
| Ask | 7.42 x 200 |
| Day's range | 7.11 - 7.51 |
| 52-week range | 1.62 - 9.00 |
| Volume | |
| Avg. volume | 197,812 |
| Market cap | 371.784M |
| Beta (5Y monthly) | 0.90 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Simply Wall St.
Hedge funds investors control 50% of TScan Therapeutics, Inc. (NASDAQ:TCRX) and were rewarded last week after stock increased 16%
Key Insights Significantly high institutional ownership implies TScan Therapeutics' stock price is sensitive to their...
- GuruFocus.com
TScan Therapeutics Inc (TCRX) Reports Increased Revenue and Expands Clinical Pipeline
Fourth Quarter and Full Year 2023 Financial Results and Business Developments
- Zacks
TScan Therapeutics, Inc. (TCRX) Reports Q4 Loss, Tops Revenue Estimates
TScan Therapeutics, Inc. (TCRX) delivered earnings and revenue surprises of 30% and 145.02%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
© 2024 Yahoo. All rights reserved.